Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2016 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial.
Sheline YI, Snider BJ, Beer JC, Seok D, Fagan AM, Suckow RF, Lee JM, Waligorska T, Korecka M, Aselcioglu I, Morris JC, Shaw LM, Cirrito JR. Sheline YI, et al. Neurology. 2020 Nov 10;95(19):e2658-e2665. doi: 10.1212/WNL.0000000000010725. Epub 2020 Sep 10. Neurology. 2020. PMID: 32913021 Clinical Trial.
RATIONALE: Serotonin signaling suppresses Abeta(42) in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram. ...
RATIONALE: Serotonin signaling suppresses Abeta(42) in animal models of Alzheimer disease (AD) and young healthy humans. In a …
Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo.
Fisher JR, Wallace CE, Tripoli DL, Sheline YI, Cirrito JR. Fisher JR, et al. Among authors: sheline yi. Mol Neurodegener. 2016 Jun 18;11(1):45. doi: 10.1186/s13024-016-0112-5. Mol Neurodegener. 2016. PMID: 27315796 Free PMC article.
BACKGROUND: The aggregation of amyloid-beta (Abeta) into insoluble plaques is a hallmark pathology of Alzheimer's disease (AD). Previous work has shown increasing serotonin levels with selective serotonin re-uptake inhibitor (SSRI) compounds reduces Abeta in …
BACKGROUND: The aggregation of amyloid-beta (Abeta) into insoluble plaques is a hallmark pathology of Alzheimer's disease
Effect of escitalopram on Abeta levels and plaque load in an Alzheimer mouse model.
Cirrito JR, Wallace CE, Yan P, Davis TA, Gardiner WD, Doherty BM, King D, Yuede CM, Lee JM, Sheline YI. Cirrito JR, et al. Among authors: sheline yi. Neurology. 2020 Nov 10;95(19):e2666-e2674. doi: 10.1212/WNL.0000000000010733. Epub 2020 Sep 10. Neurology. 2020. PMID: 32913022 Free PMC article.
METHODS: We performed in vivo microdialysis and in vivo 2-photon imaging to assess changes in brain interstitial fluid (ISF) Abeta and Abeta plaque size over time, respectively, in the APP/presenilin 1 mouse model of Alzheimer disease treated with vehicle or escital …
METHODS: We performed in vivo microdialysis and in vivo 2-photon imaging to assess changes in brain interstitial fluid (ISF) Abeta and Abeta …
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.
Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, Cirrito JR. Sheline YI, et al. Sci Transl Med. 2014 May 14;6(236):236re4. doi: 10.1126/scitranslmed.3008169. Sci Transl Med. 2014. PMID: 24828079 Free PMC article. Clinical Trial.
Serotonin signaling suppresses generation of amyloid-beta (Abeta) in vitro and in animal models of Alzheimer's disease (AD). We show that in an aged transgenic AD mouse model (APP/PS1 plaque-bearing mice), the antidepressant citalopram, a selective ser …
Serotonin signaling suppresses generation of amyloid-beta (Abeta) in vitro and in animal models of Alzheimer's disease
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.
Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Cirrito JR, et al. Among authors: sheline yi. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14968-73. doi: 10.1073/pnas.1107411108. Epub 2011 Aug 22. Proc Natl Acad Sci U S A. 2011. PMID: 21873225 Free PMC article.
Aggregation of amyloid-beta (Abeta) as toxic oligomers and amyloid plaques within the brain appears to be the pathogenic event that initiates Alzheimer's disease (AD) lesions. One therapeutic strategy has been to reduce Abeta levels to limit its accumulation. …
Aggregation of amyloid-beta (Abeta) as toxic oligomers and amyloid plaques within the brain appears to be the pathogenic event that initiate …
Reply to comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".
Sheline YI, West T, Yarasheski K, Jasielec MS, Hettinger JC, Tripoli DL, Xiong C, Frederiksen C, Grzelak MV, Bateman RJ, Morris JC, Lee JM, Cirrito JR. Sheline YI, et al. Sci Transl Med. 2014 Dec 24;6(268):268lr4. doi: 10.1126/scitranslmed.3010609. Sci Transl Med. 2014. PMID: 25540323 Free PMC article.
Possible reasons for why a new study could not replicate our finding that the serotonin reuptake inhibitor citalopram decreased amyloid beta concentrations in the cerebrospinal fluid of healthy volunteers....
Possible reasons for why a new study could not replicate our finding that the serotonin reuptake inhibitor citalopram decreased amylo …